

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S  
Form 6-K  
June 30, 2009

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 6-K  
-----

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

June 30, 2009

-----  
NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

NOVO ALLE  
DK-2880, BAGSVAERD  
DENMARK  
(Address of principal executive offices)

-----  
Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g-32(b):82-\_\_\_\_\_

TOTAL VOTING RIGHTS

TOTAL NUMBER OF VOTING RIGHTS AND SHARE CAPITAL IN NOVO NORDISK A/S AS OF 30  
JUNE 2009.

In accordance with Section 6 of the Danish Statutory Order on Issuers Disclosure  
Obligations, Novo Nordisk is required to publish the total number of voting  
rights and the size of the share capital in Novo Nordisk as per the end of the

## Edgar Filing: NOVO NORDISK A S - Form 6-K

month where changes have occurred.

Referring to Company Announcement no 35/2009 dated 22 June 2009, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk as per 30 June 2009.

|          | NUMBER OF SHARES<br>(NOMINAL VALUE<br>DKK 1) | NOMINAL VALUE (DKK) | NUMBER OF VOTES |
|----------|--|---------------------|-----------------|
| A SHARES | 107,487,200                                  | 107,487,200         | 107,487,200,000 |
| B SHARES | 512,512,800                                  | 512,512,800         | 51,251,280,000  |

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit [novonordisk.com](http://novonordisk.com).

For further information please contact:

Media:

Outside North America:  
Elin K Hansen  
Tel: (+45) 4442 3450  
[ekh@novonordisk.com](mailto:ekh@novonordisk.com)

In North America:  
Sean Clements  
Tel: (+1) 609 514 8316  
[secl@novonordisk.com](mailto:secl@novonordisk.com)

Investors:

Outside North America:  
Mads Veggerby Lausten  
Tel: (+45) 4443 7919  
[mlau@novonordisk.com](mailto:mlau@novonordisk.com)

Kasper Roseeuw Poulsen  
Tel: (+45) 4442 4471  
[krop@novonordisk.com](mailto:krop@novonordisk.com)

In North America:  
Hans Rommer  
Tel: (+1) 609 919 7937  
[hrmm@novonordisk.com](mailto:hrmm@novonordisk.com)

Company Announcement 38 / 2009

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: June 30, 2009

NOVO NORDISK A/S

-----  
Lars Rebien Sorensen,  
President and Chief Executive Officer